Prevalence of Depression among HIV-infected Persons

HIV

:HIV Human Immunodeficiency Virus !"#$ %&'(

)*+,"-./01234 567.6 8 9': ;$#1#<!"&'HIV

= #>?$"#$%@&A'B("C);D5'E1#< F4' GH1IJK*L +,MN-OPQGHR.S/01A2#$ T34U5 HIV="OV.

6AW ;D<

:7T34U5 HIV=.*8A9X":/;YAZ[;D< ZungIJ K*L+,MN-SDSAZ[;SDSB<@6.*<\] ^="'#>_^GHR.S /01MINI/.*.* `abcdef A2#$/0A*gD<9h;$HIV\T i=&7T3Aj;D^=.*8"9;>? klAZ[;D<

: SDSB<@6.*<\] ^='+2 & 8 m `f @ noD^='+ `pf'. &7gD< 9q;$ `fnoD^='B/ &9X^= +,./ῌ

"A7;D<9h^=&'/.*ῌ6@ noD< `f@ noD^='efavirenz EFVB CrDsEFVCr"6t"Eu pv*.*+/:c^,C wF xG CD.HyzI@

HIV-RNAJ HAART 6K"Pg$6t{'L|1}gD<

:~ ;Y&'EFVCr"^=66t"Eu +?$"7.^="'EFV M"Nt6OP&7.€6‚noD< ~ƒEFVM„…Q ^="'SDS12 †‡

ˆA*€‰C)Š.s‹}‰Ro1#<

: HIV= SDS efavirenz S!aŒŽ2:,2῍-- ,**0

! " #

HIV Human Immunodeficiency Virus 5R6^

= #>?$"-./0'‹#< 5R"P="

'TL UV+12?41W‘6’“o.^+,,<5R noDƒ‰”X Y "8 iZ6Z-“o•": &[

–€‰Eu —˜}“ ™šdˆ6D›(\“o+Š#

œy]^= 85R'žgD^_<67.< ŸD HAART Highly Active Antiretroviral Therapy `*"

P+*a\] b "¡DHIV=;$¢£;$

#u€6c- 8 ¤"#>(¥¦Ad-.€'E1 u1#<

HIV !"#$ %&'(

)*+,"-./012 34 567.6 8 9': ;$#1#^-῍/< §¨&'Cook“6ey(

1?A©ªy&'AIDS Acquired Immuno- deficiency Syndrome!,6«€+Šu#>f¬™d

­‡"P,6®EŠ.5;$#.⁰< ŸD g h1¯i°"P A6Š.HIV= j6±®no.#5‰7.¹< !"&'HIV

= #>?$"#$%@&A'B("C);D5 'E1#^2῍++<

~F4' GH1IJK*L +,MN-OPQ GHR.S/01A2#$ T34U5 HIV="

OV. 6AW ;D< € 9qAwF CD.HyzI@ HIV-RNAJ °k12 <}“² l; m"#>?$"/0A-.PnAC);D<

opU&' A5

³"q+**8 HIV=A;$#.< 7 T3

",**-a,´}“,**.a+,´Ÿ&  ¤"4U;$#

DHIV=r/,8 m >t6\“oD.*8A9 X":/;YAZ[;D< >tµ\'7Ust¶·Ž"¸

u=vw: ¹++-῍2.,+ xºyzº»!¼,῍+῍,

Fax :*-῍/2*,῍++3* E-mail : [email protected].

ac.jp

,**/a3´1Sj{;,**/a+,´,2Sjt

,2 ,2

Zung Zung’s Self-rating Depression Scale ; SDS + !"#$% SDS&'()*.*(+,-./012

!345$.*(67-./089:.;<=>?@

ABC Mini International Neuropsychiatric Inter- view ; MINI/.*.*- DEFGHIJKL M+!N OPQRSTUV@A! W-XY% Z[\5

]A+^A,-_^!`ab/cd67 D0L *e f DEFL 5gh$,i.cd-j&0khl m-Fnop5qh*% rs-tub0 Dv FL 5$wx$+cd6y-j&0 DzR$[L 5gh$ {% |}5$HIV~6O-€b‚&

ƒ„…OP!†ƒ$./-‡% ˆ‰5nŠ!‹ŒŽ

.*‘|$’“-”•!"#$

ῌ + Zung

Zung’s Self-rating Depression Scale ; SDS

,3

,3

῍ ῌ

HIV

SD.,., ++.+

!"#$ %$ &'()*+,-, +./, 01,121 ++ 1, 345678 9:;CD.<= SD.,*,+- cellῌmLHIV-RNA5)>/*copiesῌmL -+11./ῌ ,SDS"?=

.*@A+2 +BCMINI DEBFG 9H,+ I+BF9:

;JKLMNO%P DQBFG9H, . RS9:;TU DBFG9H,

?/+,./ῌVW: /X<

Y-VZ: [ -3.2+*.0 /.*ῌ DBFG 9H, DBFG 9

H,HIV%.efavirenz EFV Y

% DBFG 9H,EFV

\9]EFV\V^V_` c^,5; Fisher abpc*.*+/ I,VEFVd1

^efg,h` / $i 0 CD.

<= HIV-RNA HAARTVj;^e fg,h` k, -

῎ ῏

lmn6oSDS+30/VZung WWKVj pqH,r*sVjP BFt

ῐ + KLuvwxyz!b{" Mini International Neuropsychiatric Interview ; MINI /.*.* DEBF|}~(G

A+ I,€1@A #jBV 9‚ƒ+%„9$BF…‚†‡Co/:`ˆ

A, I,€1@A 9‚ƒI9V‰%hŠh;o E&oF‹hgŒ:fI9Œ:fh

Šh;o/:`ˆ

A- I,€1@A $BF 9‚ƒI9V‰%hŠh;o" h: aŽ #jBV '( /‘’:;o/:`ˆ/ r)^“:hoBCV ”

•–— /‘’:/:` *:+!˜1V”•/ῌ F/1*Kg™" -./Kg

‘– ˆ

bŽ #+jBV š,V-› 9œ ž.Ÿ o ¡/%V0¢fP £¤Š0¢fP ž

¥¦;:/Bhƒ /:`ˆ

cŽ #jBV 1§V];2:3¨4p5Šh /ogog: 6C©Ÿh

Šh ª`V«;og,hŠh/:`ˆ

dŽ #jBV 7,Y¬ /†8ho9¬/:`ˆ

eŽ #jBV r)Vsho9¬ /­^“Y¬:/:`ˆ

fŽ #jBV ®%:¯°±PI99:o9¬/:`ˆ

gŽ r)Y²F³r´±PI9¨ µ‚o,j`9¶::·œ/:`ˆ

ῐ , .* ;¸

SD

<

$i 0 CD.<=

RNA5)¹º

HAART=%

.,4,++4+

»

-1 !+ %$+ &'(+

1,1 21++ 1, .,*,+-cellῌmL

-+ 114/ῌ ,2 1*4*ῌ SD :>¼?e

-*

-*

^+,,+-,*

. !"#$%&' ( )*)+ .+,-.)/ 012+

,* 2*+ 342+567./+ 89:;

7.3+ <&=;70*+>?@A)/^+, SDS01 2+,B<&C:DEF#<>A)G^+- SDS H I<&=J ,KL7MN'7G, OPQ

7RSB<&,7MTUVWXYA)/

Z[\]7YGT ^_ `aSDS B<&

,bN)Tc&G defg8hijk lKmUG

<&=nopqrstuv/Gw=xyG

=z&7{ |}z~hlKc/'<&

=w=x/..€1..ῌ>?@A)G^+.,+/ }?@7

῍ - I<&=J >‚A)THIVƒ„ …†/‡

ˆ‰ Š‹ Œˆ CD. RNAŽ ƒ„9 HAART SDS MINI

<&= -- ‘ ,**+ .,1 ’/* MSM d.T“-TC“EFV 10 3

”<&= -0 .2 -/

,3

‘

‘

‘

‘

+331 +333 ,***

,**+

,30 --2 .*+

+0-

’/*

’/*

’/*

.,**

MSM hetero hetero MSM

AZT“-TC“EFV d.T“-TC“EFV AZT“-TC“NFV

d.T“-TC“EFV .0 .0 /- .0

. , . ,

(MSM : Men Sex with Men, d.T : Stavudine,-TC : Lamivudine, EFV : Efavirenz, AZT : Zidovudine, NFV : nelfinavir)

ῌ , I<&=J >‚A)T•1

…AZT : Zidovudine, NFV : Nelfinavir, EFV : Efavirenz

ῌ - I<&=J >‚A)TEfavirenz …EFV –-—HIVƒ„

…c^,˜‚: Fisher™š›pœ*.*+/

… -+

-+

/.*῍ HIV ^+0ῌ+3 !"#ῌ$%&ῌ'()ῌ*%ῌ+%,#

3// -./01 23,0῍4 5^,*6/ +331

Fukunishi/* HIV-0/

7 1484/² 9:;<

+,./῍5 0EFV=>?

@>EFVAB/C?

6DE EFV+3333FGH C4IJKLM$NOPQR SNon- nucleoside Reverse Transcriptase Inhibitor ; NNRTI ^,+,,, TT: !U"HVWXY1Z8 [\%#]^_1#`46ab$c%& C4 RdV'e('f SFood and Drug Administra-

tion ; FDA (R)*+g,..῍hi

*.1῍jklm C4 $ cnopq Crs i,tuv 9wEFV !xy->9:&4SDS8z {]|-}61~.€`a1/84 9: 

‚0 .i,4C1EFV ! -2ƒ/3R4„/C4

9wHIV5…66 [\%#]†7‡8GH 9ˆ>') 861H @-:‰6

Š#; ‹ [( !G<Œ@

XY8z 9w108Ž=14

quality of life1 >?-@A

8‘’-B“”•

῍ ῌ

+ CD–— ˜E™:šF›AIDSœ $ce

+0:3*3ῌ3+3 +321.

, GDHž IJKŸ  ELMž ¡˜Nž OP

Q: HIVRS¢1£KAT=œ Jpn J

Gen Hosp Psychiatry+/:01ῌ1- ,**-.

- Low-Beer S, Chan K, Yip B, Wood E, Montaner JS, O’Shaughnessy MV, Hogg RS : Depressive symptoms decline among persons on HIV protease inhibitors. J Acquir Immune Defic Syndr,-:,3/ῌ-*+,,***. . Lyketsos CG, Hoover DR, Guccione M, Senterfitt W,

Dew MA, Wesch J, VanRaden MJ, Treisman GJ, Mor- genstern H : Depressive symptoms as predictors of med- ical outcomes in HIV infection. Multicenter AIDS Co- hort Study. JAMA,1*:,/0-ῌ,/01,+33-.

/ Vedhara K, Schifitto G, McDermott M : Disease pro- gression in HIV-positive women with moderate to severe immunosuppression : the role of depression. Behav Med ,/:.-ῌ.1,+333.

0 Cook JA, Grey D, Burke J, Cohen MH, Gurtman AC, Richardson JL, Wilson TE, Young MA, Hessol NA : Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. Am J Public Health3.:++--ῌ++.*,,**..

1 Sambamoorthi U, Walkup J, Olfson M, Crystal SJ : An- tidepressant treatment and health services utilization among HIV-infected medicaid patients diagnosed with depression. Gen Intern Med+/:-++ῌ-,*,,***. 2 Fukunishi I, Matsumoto T, Negishi M, Hayashi M,

Hosaka T, Moriya H : Somatic complaints associated with depressive symptoms in HIV-positive patients. Psy- chother Psychosom00:,.2ῌ,/+,+331.

3 Inoue Y, Yamazaki Y, Seki Y, Wakabayashi C, Kihara M : Sexual activities and social relationships of people with HIV in Japan. AIDS Care+0:-.3ῌ-0,,,**.. +* Watanabe M, Nishimura K, Inoue T, Kimura S, Oka S :

Adiscriminative study of health-related quality of life assessment in HIV-+-infected persons living in Japan using the Multidimensional Quality of Life Question- naire for persons with HIV/AIDS. Int J STD AIDS+/: +*1ῌ++/,,**..

++ UVH¤ IJKŸ ¥¦WX YZ[ž: HIV

œ §%¨©ª-: 33ῌ +*. ,**+.

+, \«¡:¬]SSDSœ£7š-:,.*ῌ,./

+333.

+- ^_`Ta ­¡Pbž ®c—¯ °Y—± d

—²: Zungj³´cµ:‰¬]rG¶e·:

‰¬]$cA&¸4Cœ $ce-*: 33+ῌ330 ,**+.

+. 2¹º+ f¦P»ž gh—Ta:A i¸œ $ce,-:/ῌ+, +33..

+/ YECp jE—k:;dr“Œl

¼œ $m/3:+...ῌ+..3 ,**+.

+0 Atkinson JH Jr, Grant I, Kennedy CJ, Richman DD, Spector SA, McCutchan JA : Prevalence of psychiatric disorders among men infected with human immuno- deficiency virus. Acontrolled study. Arch Gen Psychia- try./:2/3ῌ20.,+322.

+1 Emmelkamp PM : Psychosocial factors in HIV-AIDS.

Psychother Psychosom0/:,,/ῌ,,2,+330. S -,

-,

+2 Brown GR, Rundell JR, McManis SE, Kendall SN, Zachary R, Temoshok L : Prevalence of psychiatric dis- orders in early stages of HIV infection. Psychosom Med /.:/22ῌ0*+,+33,.

+3 Penzak SR, Reddy YS, Grimsley SR : Depression in pa- tients with HIV infection. Am J Health Syst Pharm/1: -10ῌ-20,,***.

,* Maj M, Janssen R, Starace F, Zaudig M, Satz P, Sug- hondhabirom B, Luabeya MA, Riedel R, Ndetei D,

Calil HM : WHO Neuropsychiatric AIDS study, cross- sectional phase I. Study design and psychiatric findings.

Arch Gen Psychiatry/+:-3ῌ.3,+33..

,+ Adkins JC, Noble S : Efavirenz. Drugs/0:+*//ῌ+*0., +332.

,, :

!"#$%&'( )*

+0:3+ῌ31 ,***.

Prevalence of Depression among HIV-infected Persons

Kazunori M

, Toshio N

, Masazumi Y

, Naoto T

, Hiroshi F

, Tetsu O

, Hiroshi I

, Suminobu I

, Takashi D

and Yasuo H

Department of General Medicine, Juntendo University School of Medicine

Introduction: There have been a variety of reports in the U.S. and Europe on the relationship between depression and HIV infection, including the e#ects of depression on disease progress and mortality rates, but the results have been inconclusive. In Japan there have been fewer reports that have statistically analyzed the mental states of multiple patients with HIV infection. Therefore, we used a simple, self-rating depression scale (SDS) to study the prevalence of depression among HIV-infected persons visiting our outpatient clinic.

Subjects and Methods: We conducted a cross-sectional study of.*HIV-infected patients visiting our outpatient clinic. We interviewed patients whose total SDS scores were.*or more, using the Major Depression Episode criteria in mini international neuropsychiatric interview (MINI). We conducted the same procedure on.*patients who were visiting our outpatient clinic for reasons other than HIV infection ; these patients formed the control group.

Results: Eighteen patients had SDS scores of.*or more. One of these was assessed as having major depression and . were determined to have minor depression. A total of / patients (+,./ῌof the subject group) were assessed as having depression. In the control group,/.*ῌwere judged as having depression. Significantly more patients taking efavirenz had depression than those not taking efavirenz (P+*.*+/: chi-squared test). Di#erences in infection route, nationality, number of CD.-positive cells, HIV-RNA level, and HAART regimen were not significantly correlated with di#erences in prevalence of depression.

Conclusion: There was a significantly greater rate of depression among HIV patients taking efavirenz, suggesting that caution is needed when administering this drug to depressed patients. It may be advisable to conduct depression tests such as the SDS on patients who are to be treated with efavirenz.

Key words: HIV-infected person, depression, SDS, efavirenz

, -- --